Renown Health Patients and Visitors

RENOWN NEWSROOM

Latest News Releases

Featured News

Careers

Awards & Accreditations

University of Nevada, Reno

Renown Health Foundation



Media Resources

Renown Public Relations Media Icon
Renown Health's Public Relations Team
news@renown.org

Renown Health's public relations team supports media partners in finding experts on diverse health care topics. In addition, we provide information and answer all questions regarding Renown. We look forward to working with you.

Read MoreMedia Resources
  • Media On Campus

    For patient confidentiality purposes, Renown Health policies require media to be escorted by the public relations staff at all times.

    PR staff will gladly make parking arrangements, notify the appropriate hospital staff and help you find your destination.

     

    Stand Ups/Live Broadcasts

    Media may conduct stand ups and live broadcasts on our campuses. In the interest of patient confidentiality and traffic flow, a staff member will help you find the best location for your story.

    We ask you to respect our obligation to protect our patients' well-being and legal right to privacy.

  • Patient Condition Inquiry

    We follow regulations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) for all patients, including patients of public interest. HIPAA regulations specify which information may and may not be released without authorization from a patient.

    Patient privacy regulations allow us to only share patient condition information about patients that appear in our directory.

    Media inquiries require correct spelling of the patient's first and last name.

     

    Definitions of "Condition" used by Renown Health

    When describing a patient's condition, we can only release the following patient statuses:

    Good - Vital signs such as pulse, temperature and blood pressure are stable and within normal limits. Patient is conscious, comfortable and there are no complications.

    Fair - Vital signs are stable and within normal limits. Patient is conscious and alert although may be uncomfortable or in pain and may have minor complications.

    Serious - Vital signs may be unstable or outside normal limits. The patient is acutely ill or injured and may have major complications.

    Critical - Vital signs are unstable or outside normal limits. There are major complications.

    Note: "Stable" is not a condition.

Press Releases

Number of results found: 13
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page # 2 Navigate to next page Page 1 of 2
Skipped to 13 results found. Page 1 of 2
    • Monday, Mar 18, 2024

    Filling The Community’s Need for a 24/7 Pharmacy: Beginning April 29, Renown Pharmacy – Pringle Will Be Open 24/7

    Weeks after the only 24/7 pharmacy in Reno-Sparks announced it is no longer open overnight, Renown steps up to fill the community’s need, offering peace of mind knowing that any time, day or night, people can fulfill their essential medication prescriptions at Renown Pharmacy. Renown Health is pleased to announce that beginning on Monday, April 29, Renown Pharmacy - Pringle will expand hours to serve as the only 24/7 pharmacy in the area to serve all customers. The Renown Pharmacy located inside Renown Regional Medical Center will fill a gap left in the community after Walgreens on N. Virginia Street in Reno announced that they will no longer operate on a 24-hour, seven day a week schedule. Renown’s “all-hours, around the clock” pharmacy access will allow patients post-discharge from any area hospital the ability to fill their pharmaceutical prescriptions at any time, along with granting all community members the opportunity to pick up their prescriptions when it is most convenient for them. “We are proud to be able to step up to provide round-the-clock access to essential medications and healthcare services for our growing community, said Brian Erling, MD, MBA, President & CEO for Renown Health. “We understand the importance of accessibility to medications and healthcare support, especially during times of urgent need. Our decision to operate our pharmacy 24 hours a day, 7 days a week, reflects our commitment to serving the needs of our community and ensuring individuals have convenient access to the care they need, day and night.” “We are grateful for the pharmacy service that Walgreens provided the Reno-Sparks area for many years. We are excited that Renown can now provide our community with access to 24/7 Rx care,” said Adam Porath, Pharm.D., BCACP, BCPS, FASHP, Renown Health Vice President of Pharmacy Services. “By offering continuous pharmacy services, we aim to provide peace of mind to our customers and community- knowing that they can rely on us, any time, day, or night, to fulfill their prescription needs and offer professional guidance on medication management. Our talented team of pharmacists and techs are eager to serve our community with the Renown Pharmacy at Renown Regional Medical Center, starting Monday, April 29.” “In times of illness, timely access to medications is crucial for effective treatment and swift recovery. Whether its managing chronic conditions or addressing acute symptoms, adhering to prescribed medication schedules can significantly impact one’s health outcomes,” said Bill Plauth, MD, MMM, CPE, Chief Medical Officer for Renown Health. We believe that by extending our pharmacy hours, we can better support the health and well-being of our community, ensuring they receive care they deserve when they need it most. We invite our people to take advantage of our expanded pharmacy and experience the convenience and reliability of our 24/7 services.” Renown Pharmacy - Pringle is conveniently located on the first floor of Renown Regional Medical Center in Reno. The Renown Pharmacy is near Starbucks and specializes in hard-to-find pharmaceuticals at lower costs, such as certain compound medications not typically stocked at other retail locations. Prescriptions can be transferred to any of Renown’s three retail pharmacy locations by calling the most convenient location and allowing expert pharmacy staff to complete the process. You can then request refills and check your prescription status in the MyChart app. Renown Pharmacy Pringle, 75 Pringle Way: 775-982-7737 Renown Pharmacy South Meadows, 10101 Double R Blvd.: 775-982-5366 Renown Pharmacy Locust, 21 Locust St.: 775-982-5280 For full pharmacy information, visit: renown.org/pharmacy/. Renown Health continues to expand and hire in-demand clinical positions, including positions at Renown Pharmacy. Visit renown.org/careers to learn more.     About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®.

    Read More About Filling The Community’s Need for a 24/7 Pharmacy: Beginning April 29, Renown Pharmacy – Pringle Will Be Open 24/7

    • Monday, Jan 29, 2024

    Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division

    Renown Health is pleased to announce that Kate A. Ward, Pharm.D., BCPS, has been promoted to serve as Vice President, Oncology for Renown Regional Medical Center.    Dr. Ward has over fourteen years of service to the organization, most recently as Director of Clinical Pharmacy responsible for the oversight of all clinical pharmacy activities at Renown Regional Medical Center, Renown South Meadows Medical Center, and Renown Rehabilitation Hospital. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown. Over the last decade at Renown, Dr. Ward has served as Pharmacy Clinical Manager, Pharmacy Clinical Coordinator and Clinical Pharmacist.   Dr. Ward will bring her pharmacy clinical service experience (including ICU, Outpatient Infusion, Pediatrics, Oncology and Emergency Services), Inpatient Care, Clinical Research, and Hospital Formulary Management, Electronic Medical Record Integration and Optimization to this important new role.   As a dyad partner with Max J. Coppes, MD, PhD, MBA, Director of the William N. Pennington Cancer Institute at Renown, she will bring her clinical, operational, regulatory, and administrative experience to lead the oncology division. Dr. Ward, Dr. Coppes and the dedicated team will advance Renown’s mission to expand care, prevention, screening, research, and education with the goal of establishing the first National Institutes of Health, NCI designated Cancer Center for our State.   “We are thrilled to welcome Dr. Ward as our new Vice President of Oncology. She brings a wealth of experience and a passion for advancing patient care. Dr. Ward will play a pivotal role in sharing the future our oncology division and furthering our commitment to providing exceptional care,” said Chris Nicholas, CEO of Renown Regional Medical Center.    As a licensed pharmacist, Dr. Ward holds a Doctor of Pharmacy degree from the University of Colorado, Health Sciences Center. The Pharm.D. is a professional degree like a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists.    Dr. Ward completed her residency at Stanford Hospital and Clinics. She graduated from the University of Nevada, Reno with her bachelor’s degree in Nutritional Sciences. Dr. Ward is active in several professional associations and currently serves as a Pharmacy Board member for HealthTrust; Vice Chair of the American Society of Health System Pharmacists® Council on Therapeutics; and Vice Chair for the Silver State Scripts Board for the State of Nevada. Dr. Ward was the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. To join the Renown Health team, visit renown.org/careers.

    Read More About Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division

    • Tuesday, Dec 19, 2023

    Give the Gift of Health This Season with ELF Testing

    Renown Health and the University of Nevada, Reno School of Medicine give the gift of early diagnosis and disease prevention this holiday season.   With the season of giving upon us, give yourself the gift of health. The Renown Institute for Health Innovation (IHI) and the University of Nevada, Reno School of Medicine (UNR Med) are excited to offer a free Enhanced Liver Fibrosis (ELFTM) test to patients at risk for a common type of liver disease, e.g. metabolic and nonalcoholic steatohepatitis (M/NASH), and who enroll or are currently enrolled in the Healthy Nevada Project. The ELF Test is an FDA (Food and Drug Administration) approved non-invasive test to help identify people most at risk for liver scarring, e.g. cirrhosis, and allows doctors to intervene before irreversible damage occurs. If undetected and untreated, M/NASH can result in liver cirrhosis which could require liver transplantation or lead to death. This test is important as the symptoms of M/NASH can be silent or non-specific, making it difficult to diagnose.  “There are currently more than 11,000 people across the U.S. on the national liver transplant waiting list, and with the heightened prevalence of NAFLD and M/NASH, this number is projected to keep rising; however, with research such as the ELF Test at our disposal, we are continuing to find ways to improve the health of those at risk for advanced liver disease,” said Bill Plauth, MD, Chief Medical Officer for Renown Health and Associate Dean of Clinical Affairs at UNR Med. “We encourage our community to participate in this early risk detection. Through this sophisticated, noninvasive, blood test, our physicians and Advanced Practice Providers can better evaluate liver fibrosis to help those affected and enable researchers to improve the prevention and treatment of nonalcoholic liver disease as a whole.”  This liver health-focused sub-study of the Healthy Nevada Project seeks to enhance the understanding of both NAFLD and M/NASH and to help inform the development of treatment options for these conditions, as few currently exist. “Providing access to cutting-edge innovations such as the ELF Test is critical for both participants and the physicians and advanced practice providers that care for them.” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project and the Liver Disease Study and research professor at UNR Med. Those interested in determining their risk for M/NASH and its progression are encouraged to enroll in the Metabolic & Nonalcoholic Steatohepatitis study. Those who have consented and participated in the M/NASH research will be eligible and contacted with more information on how to receive the ELF Test. The Renown IHI is also happy to connect with physicians and Advanced Practice Providers interested in having their patients enroll in the Healthy Nevada Project and join the study. For members of the community who would like more information and learn how to enroll, please contact the Renown IHI at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About the ELF™ Test  The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. For more information or to enroll, please contact RenownIHI@renown.org or (775) 982-6914. In the U.S., the ELF Testing Service is available from Brio Clinical, Inc., a CLIA-certified laboratory offering specialized testing throughout the United States. Brio Clinical is regulated under CLIA as qualified to perform high complexity testing.

    Read More About Give the Gift of Health This Season with ELF Testing

    • Wednesday, Oct 05, 2022

    Newly Expanded Clinical Research Center at UNR Med Fosters Collaboration and Research with Renown Health

    Renown Health and the University of Nevada, Reno School of Medicine (UNR Med) are proud to announce a newly integrated and expanded research space called the Clinical Research Center (CRC). This space offers a dynamic physical location on the University of Nevada, Reno campus that supports the UNR Med and Renown Health research enterprise. "The partnership between Renown Health and UNR Med truly knows no bounds, and this Clinical Research Center is an incredible example of that endless possibility,” said Thomas Graf, MD, interim CEO of Renown Health. “This new space will only continue to expand our community’s access to clinical research as part of patient care while providing the necessary resources to engage our students and support a healthy Nevada.” This space’s capabilities include experienced staff with knowledge and skills in operationalizing FDA and non-FDA regulated clinical and translational research studies in a centralized 5,470-square foot research clinic housed in the Center for Molecular Medicine (CMM) at the University. This CRC space provides resources including: A centralized location next to the laboratory space that allows for strategic interdisciplinary collaboration between clinicians and basic scientists. Eleven private outpatient rooms for research clinic visits. Two blood draw stations. Physician consultation areas. Conference room for trial monitoring and consulting. Secure Investigational Product storage and preparation. Sample processing and storage, including countertop refrigerated centrifuges, 4°, -20° and -80° C refrigerators and freezers. Operations around clinical research are becoming more complex so growing clinical research in our community will require expertise and dedicated space where clinical research can be conducted in a learning environment first,” said Danielle Eaton, Director of Clinical Research with UNR Med and Renown Health. “This Clinical Research Center provides such space and experienced staff where these research studies can be successfully completed. The CRC provides a training environment for students, residents, faculty and clinical research professional work-force that will be needed to bring cutting edge diagnostics, therapeutics and preventatives to our community.” Meet the Team: Danielle Eaton, UNR Med Director of Clinical Research Kristen Gurnea, Renown Health Manager of Clinical Research Amber Emerson, UNR Med Project Manager Valerie Smith, UNR Med Center Administrative Manager Annie Beach-Hills, Gina Castro, Michelle Mejia and Amil Trujillo-King, UNR Med Study Coordinators Dr. John Westhoff, UNR Med Chair of Internal Medicine, Emergency Medicine physician Dr. Sean Kandel, UNR Med Associate Program Director for Resident Research, Associate Professor of Internal Medicine Dr. Amneet Rai, UNR Med Clinical research pharmacist Dr. Kellie Watkins, UNR Med Clinical Epidemiologist/Data Manager/Statistician As part of the affiliation between UNR Med and Renown Health, the Clinical Research Office is part of an integrated Office of Clinical Research, which allows both entities to collaborate on shared research program objectives. This effort allows colleagues to partner on clinical research, and to leverage bench-to-bedside research and delivery of leading-edge healthcare to northern Nevadans. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. About UNR Med   The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first public medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Since 1969, UNR Med has trained more than 3,900 students, residents and fellows. UNR Med continues to improve the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

    Read More About Newly Expanded Clinical Research Center at UNR Med Fosters Collaboration and Research with Renown Health

    • Monday, Oct 03, 2022

    Renown's Dr. Kate Ward Honored with Nevada Society of Health System Pharmacists (NVSHP) President's Award

    The award is given annually to a member of the Nevada pharmacy community making significant and sustained contributions to the field Kate Ward, Pharm.D., BCPS Director of Clinical Pharmacy at Renown Health is the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. Dr. Ward has been with Renown for over a decade, starting as a Clinical Pharmacist in 2009. As the Director of Clinical Pharmacy, she is responsible for the oversight of all clinical pharmacy activities at Renown Regional, South Meadows and Rehab. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown Regional Medical Center. “We are so proud that Kate has been recognized by the Nevada Society of Health System Pharmacists with the President’s Award and for her many accomplishments as a member of our Renown Pharmacy team. With 66% of adults taking five or more drugs per day and 27% taking 10 or more per day, a pharmacist’s review is critical in supporting patient safety and well-being,” says Tom Graf, MD, interim CEO, Renown Health. “Beyond that, pharmacists have the ability to suggest methods for accurately and effectively taking prescribed medications, discuss medication safety, identify and manage side effects and assist patients and families in managing chronic health conditions.” As a licensed pharmacist, Dr. Ward holds The Doctor of Pharmacy degree (abbreviated Pharm.D. or PharmD) from the University of Colorado. The Pharm.D. is a professional degree similar to a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists. The Doctor of Pharmacy degree takes three to four years of undergraduate pre-professional (prerequisite) coursework, followed by four academic years in a professional program. Most students need four years to complete their prerequisite courses. Thus, it usually takes eight years of college study to earn a Pharm.D. and become a pharmacist. Pharmacists working in hospitals and health systems often complete additional post-graduate training after a Pharm.D. degree. Dr. Ward completed a PGY1 Residency at Stanford prior to joining the Pharmacy Department at Renown. “Dr. Ward is such an asset to Renown and our community. Her incredible perseverance to reach for and achieve higher aspirations has resulted in this important recognition by our peers across the state. She consistently contributes her pharmacy expertise to patients, physicians, clinicians and healthcare students and volunteers her time to advance the profession at both the state and national level through pharmacy professional organization participation. It is wonderful to have her efforts recognized by NVSHP,” says Adam Porath, Pharm.D., BCACP, BCPS, FASHP, Vice President, Pharmacy. On Sept. 24, NVSHP and the Nevada Pharmacy Alliance held their annual joint meeting at Renown Regional Medical Center. During this meeting, Dr. Ward was awarded the NVSHP President’s Award. The President’s Award is awarded annually at NVSHP President's discretion to a member making significant and sustained contributions to NVSHP. Dr. Ward was specifically recognized for representing the State of Nevada at the American Society Health System Pharmacists House of Delegates for several consecutive years, as well as her continuous contributions to the annual NVSHP Student Symposium. Established in October 2006, NVSHP has diligently worked on continuing the strong foundation developed to better meet the needs of health-system pharmacists in Nevada. The organization was established on a strong mission statement that enables Nevada's pharmacists to be heard, from all regions of the state and in one collective voice to advocate for patient care. Are you interested in working with this award-winning team? The Renown Health Pharmacy is hiring for multiple roles, including pharmacy technician and clinical pharmacist. For more information, visit careers.renown.org. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 6,500 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®.

    Read More About Renown's Dr. Kate Ward Honored with Nevada Society of Health System Pharmacists (NVSHP) President's Award

    • Wednesday, Apr 27, 2022

    Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result

    Released in partnership with the Desert Research Institute: New research from the Healthy Nevada Project® finds that a confirmed diagnosis does not always result in changes to patient care. Presenting individuals with potentially life-altering health information doesn’t mean the individuals – or their healthcare providers – will act on it. Follow-up education and conversations about actionable care plans with patients and their doctors are key next steps, according to new research from the Healthy Nevada Project.  The Healthy Nevada Project is a genetic screening and research project that launched in 2016 as a partnership between DRI and Renown Health. The project now has more than 50,000 participants, with genetic sequencing provided by Helix.  Between September 2018 and September 2020, the Healthy Nevada Project successfully notified 293 participants that they were genetically at risk for hereditary breast and ovarian cancer syndrome, Lynch syndrome, or familial hypercholesterolemia – three common genetic conditions known collectively as the Centers for Disease Control and Prevention (CDC) Tier 1 conditions. In a study published today in Frontiers in Genetics, Healthy Nevada Project scientists looked at the impact that notifying a patient of a positive finding for a CDC Tier 1 condition had on the care that the patient received in the months and years that followed.  According to their results, among the 293 Healthy Nevada Project participants who were notified of their genetic risk of a CDC Tier 1 condition, 71 percent of participants with electronic health records shared their findings with healthcare providers. However, only 30 percent of the electronic health records for these patients contained documentation of the genetic diagnosis, and only 10 percent of examined patients experienced a possible change in care after receiving the results of their genetic screening.  “The Healthy Nevada Project was implemented with a ‘hands-off’ approach where the participants receive their findings and decide with whom and when to share those findings. The findings were not automatically added to their electronic health records,” said Dr. Gai Elhanan, health data scientist at DRI and co-lead author of the study. “What we’re learning now is that to ensure that important genetic findings are integrated into the care journey it is important to make their inclusion into the electronic health records part of the study.” This study builds on previous Healthy Nevada Project research published in Nature Medicine demonstrating the importance of screening for CDC Tier 1 conditions, which affect about one in 75 individuals and can be mitigated or even prevented from developing into disease when detected early. This study found that as many as 90 percent of the CDC Tier 1 cases are missed by clinical providers during normal clinical care screenings and examinations. During the current study, the Healthy Nevada Project scientists found that 19 percent of studied participants had already developed one of the CDC Tier 1 conditions, and thus would have potentially benefited from earlier notification about their condition. The study team hopes that their findings will encourage individuals in Nevada to obtain genetic testing for these relatively common conditions. Even if individuals are older or have already suffered from diseases related to these conditions, testing could also prove beneficial to siblings, children, and grandchildren who may also be at risk and who could subsequently be screened in the event of a positive finding. The study team also encourages informing health care providers of the importance of incorporating genetic diagnoses into the pharmaceutical (for example, for Familial Hypercholesterolemia) and treatment advice given to patients.  “As a result of this analysis, the clinicians at Renown Health and the Healthy Nevada Project researchers have made significant changes, including obtaining informed consent from participants to report positive findings from their genetics reports directly into their electronic medical record,” said Daniel Kiser, M.S., assistant research scientist of data science at DRI and co-lead author of the study. “This will help both participants, their clinical providers, and the whole state maximize the long-term benefits of the Healthy Nevada Project voluntary population-based genetic screening.” Additional information: The full text of the study,  Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, is available from Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169.  This project was funded by Renown Health, the Renown Health Foundation, and the Nevada Governor’s Office of Economic Development. Study authors included Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix), and Joseph Grzymski (DRI/Renown Health). For more information on the Healthy Nevada Project® or to request genetic screening, please visit: https://healthynv.org/ About DRI The Desert Research Institute (DRI) is a recognized world leader in basic and applied environmental research. Committed to scientific excellence and integrity, DRI faculty, students who work alongside them, and staff have developed scientific knowledge and innovative technologies in research projects around the globe. Since 1959, DRI’s research has advanced scientific knowledge on topics ranging from humans’ impact on the environment to the environment’s impact on humans. DRI’s impactful science and inspiring solutions support Nevada’s diverse economy, provide science-based educational opportunities, and inform policymakers, business leaders, and community members. With campuses in Las Vegas and Reno, DRI serves as the non-profit research arm of the Nevada System of Higher Education. For more information, please visit www.dri.edu. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision making. Learn more at www.helix.com.

    Read More About Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result

    • Tuesday, Dec 15, 2020

    Renown Institute Expands Partnership to Offer ELF Testing

    Together, will test over 30,000 qualifying study participants by 2023 for risk of cirrhosis and liver-related illnesses. Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens Healthineers to offer the Enhanced Liver Fibrosis (ELF™) Test to people with risks for nonalcoholic steatohepatitis (NASH) enrolled in the Healthy Nevada Project (HNP). The ELF Test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes and allow healthcare providers to intervene before irreparable damage occurs. This noninvasive blood test uses three serum biomarkers to create an ELF score from a predefined algorithm, which can be used by doctors to help evaluate if a patient requires increased medical care and monitoring for their condition. Nonalcoholic fatty liver disease (NAFLD), which includes NASH, is prevalent in Nevada and under-diagnosed, likely affecting more than 500,000 adult Nevadans. If undetected and untreated, NASH can result in liver cirrhosis and may require liver transplantation or lead to death. There are more than 12,000 people on a waitlist for liver transplantation in the U.S. and this number continues to rise due to the increasing prevalence of NAFLD. “Thanks to important data collected through our Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study, we now know that NASH is prevalent in the state of Nevada,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health. “We are proud to expand our partnership with Gilead and begin working with Siemens Healthineers to improve health of those with liver disease and to take early detection one step further by offering Enhanced Liver Fibrosis, ELF testing for patients of Renown Health. This test provides our team of highly-skilled physicians an advanced, noninvasive method to actively assess dynamic liver fibrosis in study participants and intervene whenever necessary, contributing to a healthier Nevada.”  “Gilead believes that noninvasive tests, including the ELF Test, will help improve the experience of people living with NASH. These tests may help to diagnose liver disease, monitor disease progression and evaluate responses to treatment without the requirement for liver biopsy,” said Rob Myers, MD, Vice President, Liver Fibrosis Clinical Research at Gilead Sciences. “The ELF Test has proven itself to be a valuable tool in NASH management and we hope this partnership will further support its use in routine care.”  “We are very pleased that NASH patients in the Healthy Nevada Project now have access to the ELF Test which offers clinically useful prognostic information for their condition with the convenience of a simple blood test. Using our advanced laboratory expertise together with Renown IHI and Gilead, we can work towards better understanding of NASH and liver disease in a representative patient population,” said Sebastian Kronmueller, Head of Molecular Diagnostics at Siemens Healthineers. “We launched the Healthy Nevada Project to help people understand more about their health, to identify serious health risks, and to give people access to innovations like the ELF Test, so they can live their best lives,” said Renown’s chief scientific officer, Dr. Joseph Grzymski, who is also a research professor at the Desert Research Institute and principal investigator of the Healthy Nevada Project. It’s incredibly rewarding to be able to report clinical findings to help our 50,000 volunteer study participants, and to assist healthcare providers in helping their patients.” The provision of the ELF Test builds on a previously announced strategic collaboration between the Renown IHI and Gilead in July 2019. This ongoing partnership aims to collect and analyze de-identified genetic and electronic health data from 60,000 qualifying study participants to enhance the understanding of NAFLD and NASH and to potentially inform development of treatment options for these diseases.  About NAFLD and NASH NAFLD is a build-up of fat in the liver of people who do not have a history of alcohol misuse. It is normal for the liver to contain some fat, but if more than 5 percent of the liver content is fat, it’s considered a fatty liver (steatosis). NASH is the most severe form of NAFLD in which a person has liver cell damage and inflammation of the liver. Inflammation and liver cell damage can cause fibrosis, or scarring of the liver, and can cause decreased liver function (1). The symptoms of NASH are often silent or non-specific, making it difficult to diagnose. About one-third of people with NASH develop cirrhosis or irreversible liver damage (2). About the ELF™ Test The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. For more information or to enroll, please contact RenownIHI@renown.org or (775) 982-6914. The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.  In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information visit, renown.org. About the Renown Institute for Health Innovation Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org. Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has over 60,000 participants. For more information, visit healthynv.org.  About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.Media Contact for Siemens Healthineers: Lance LongwellM: 610-448-6341E: lance.longwell@siemens-healthineers.com

    Read More About Renown Institute Expands Partnership to Offer ELF Testing

    • Friday, Oct 16, 2020

    Renown Health Welcomes New Vice President, Pharmacy

    Adam D. Porath, Pharm.D., BCACP, BCPS-AQ Cardiology is promoted to serve future generations and improve the health and well-being of Nevadans. Renown Health is excited to announce Dr. Adam Porath has been promoted to vice president, pharmacy to lead clinical pharmacy and pharmacy operations and ensure excellent care for patients and families.  “We are pleased to promote an experienced and talented leader like Dr. Adam Porath,” said Dawn D Ahner, DSc, FACHE, Chief Operating Officer, Acute Services. “Adam will continue to foster a culture of caring and excellence, while ensuring the highest level of pharmacy practice and experience for both care providers and patients.”  Dr. Porath has served in roles within pharmacy at Renown since 2006. Since June 2020, he has served as Interim Director of Pharmacy where he has led strategic planning for pharmacy operations, precepted students and residents, identified business growth opportunities, developed novel clinical pharmacy services and oversaw quality assurance of pharmacy operations. He began his career as a pharmacy practice resident at Renown Regional Medical Center in Reno.  “I am honored to be given the opportunity to serve the medical community and patients of Renown Health,” said Dr. Porath. “What a source of pride it is to be able to deliver the high-quality, compassionate patient care Renown is known for, and to help serve and lead in the pharmacy profession.” Dr. Porath received his doctor of pharmacy degree from Idaho State University. He is a board certified pharmacotherapy specialist with added qualifications in cardiology and board certified ambulatory care pharmacist. Dr. Porath has a BS in Biology from the University of Nevada, Reno.  Dr. Porath serves as adjunct clinical faculty for several colleges of pharmacy including the University of New England, Oregon State University, University of New Mexico, Idaho State University and University of Wyoming. He has been published in several peer-reviewed journals including CHEST, Clinical Infectious Diseases, and the Canadian Medical Association Journal.  Here in Nevada, Dr. Porath successfully lobbied the Nevada Legislature on behalf of the Nevada Society of Health System Pharmacists (NVSHP) to pass Collaborative Drug Therapy Management (CDTM) legislation in 2011, permitting Nevada pharmacists to adjust drug therapy per physician-signed protocol in any practice setting, as long as the pharmacist is under a physician’s direct supervision. Currently, 48 states permit some degree of CDTM. In 2017, Adam helped to pass further expansion of the pharmacy practice act. He is currently serving as a director at large of the NVSHP board. Dr. Porath has served as a state of Nevada delegate to the American Society of Health System Pharmacists (ASHP) House of Delegates since 2012. In 2018, Dr. Porath was appointed to the Nevada Attorney General’s statewide partnership on the opioid crisis. In 2019, he was appointed to the ASHP Council on Public Policy.  In U.S. News and World Report Best Hospital rankings, Renown South Meadows Medical Center was listed #1 in the State of Nevada. Renown Regional Medical Center was named #2 Best Hospital in Nevada. A hospital's score is based on multiple data categories, including patient outcomes, safety and volumes. Hospitals earning a high performing rating were significantly better than the national average.  About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project® . For more information, visit renown.org.

    Read More About Renown Health Welcomes New Vice President, Pharmacy

    • Thursday, Sep 03, 2020

    Could Private Well Water Unlock Health Insights?

    The Healthy NV Project® launches a new study to identify how private well water could impact the health of those living in the household. You use your faucet to wash your hands, make coffee and fill your water bottle. However, for approximately 41,000 people in Washoe and Churchill Counties who rely on private well water, there may be unseen contaminants present in their H2O, which could be affecting their health. The Healthy Nevada Project®, with support from the National Institutes of Health (NIH), is launching a new study to discover how private well water quality impacts the health of well owners. By providing free water testing kits to interested Healthy Nevada Project® participants, researchers will collect samples and give results back to well owners, along with resources for potential treatment options. Data from previous studies in Nevada show elevated concentrations of heavy metals in some private, household wells. Since water from household wells is not monitored for quality by government agencies, well water testing helps ensure water does not contain dangerous levels of heavy metals, such as lead, which can lead to adverse health impacts.  Those with a household well interested in receiving a free water testing kit must be enrolled in the Healthy Nevada Project’s population genetic screening study and consent to be a part of further research. People interested in joining the study can simply sign up to receive a genetic spit test kit in the mail or join the waitlist to be notified when in-person testing resumes. “The goals of the Healthy Nevada project are to improve population health and better understand processes that increase disease risks, such as cancer. In this study, we engage with our study participants and inform them about the impact of the environment on their health, while researching environmental contaminants that may elevate cancer risk,” said Joseph Grzymski, Ph.D., research professor at DRI, principal investigator of the Healthy Nevada Project® and chief scientific officer for Renown Health. “During a time where people are spending more time at home, we’re excited to launch this multi-disciplinary study that dives into possible health impacts of a household’s water source.”  “As the Healthy Nevada Project continues to serve over 54,000 research volunteers, we are proud to provide helpful information to participants, so they can make life-changing improvements to their home environment,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health and co-director of the Healthy Nevada Project. “This allows every person with well water in Nevada, to have important information, at no charge, to help live healthier and better lives and to protect their family’s health.” The Healthy Nevada Project® is the fastest-enrolling genetic study in the country. The Project is also the first of its kind to return clinical results to study volunteers, which means participants can learn their genetic risks tied to heart disease and certain cancers, as well as lifestyle changes that could potentially help reduce their risk and prevent disease. To enroll in the Healthy Nevada Project, please visit healthynv.org.      Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org.

    Read More About Could Private Well Water Unlock Health Insights?

    • Wednesday, Jul 29, 2020

    Renown Pharmacy Introduces New Program: Medications to Go

    Renown's Medications to Go program offers time-savings and convenience for patients and their families. It can be difficult leaving the hospital after a stay. Learning and understanding detailed care instructions and settling in to a new routine, can be an overwhelming experience for both patients and their caregivers. Plus, there’s the added inconvenience of visiting the pharmacy to pick up prescribed medications.  Because it is so inconvenient, one-third of these prescriptions never reach the patient, and remain in a basket at the pharmacy, awaiting pick-up. Because the patient never takes their medication, recovery time can take longer, and in some cases, the patient goes without the needed medications and may be readmitted to the hospital.   To make the process more convenient for patients and their families, Renown Pharmacy now offers a new Medications to Go program.  Patients can now receive Medications to Go at Renown hospitals. Opting in when they arrive, and the day they leave, their medication will be hand-delivered to them in their room by a member of Renown’s pharmacy team, along with medication counseling by a Renown pharmacist. There is no additional cost for patients to use this service aside from their normal medication copays. “Medications to Go is another example of how we are using new approaches to deliver an excellent patient and customer experience, and helping people choose, access, experience and prefer Renown Health providers and hospitals,” said Tony Slonim, MD, DrPH, president and CEO of Renown. “We want to help our patients on their journey to health and wellness.”  The Renown Pharmacy team has been recognized for several national best practice programs. A similar pilot program showed a 25 percent reduction in hospital readmission rates for patients with Medicaid insurance, emphasizing the need for the service for all patients at all Renown hospital locations. Since June 1, 2020, Medications to Go has been available to every patient at Renown Regional Medical Center, Renown South Meadows Medical Center and Renown Rehabilitation Hospital. “We’ve filled more than 1,600 prescriptions through the program to date,” said Adam Porath, Doctor of Pharmacy, and Renown’s interim director. “Patients are very happy – especially new moms and parents of our youngest patients at Renown Children’s Hospital.”      About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

    Read More About Renown Pharmacy Introduces New Program: Medications to Go

    • Friday, May 08, 2020

    Seeking Donors Who Have Recovered from COVID-19 to Donate Plasma

    New study, led by physician researchers from Renown Health and University of Nevada, Reno School of Medicine seeks to understand how the immune system responds to COVID-19 with goal of developing a new treatment. Individuals who have recovered from COVID-19 may now be able to help patients currently fighting the infection by donating their plasma. Those who have recovered from the infection may have COVID-19 antibodies in their blood. These antibodies provided one way for their immune systems to fight the virus when they were sick, so their blood may be used to help others fight off the disease through convalescent plasma. Convalescent plasma is a component of blood from recovered patients that may contain precious COVID-19 antibodies. Antibodies are proteins that might help fight the infection. In this study, we will be collecting plasma from patients who have recovered from COVID-19 and investigating its efficacy in helping treat other patients with COVID-19. Convalescent plasma is being investigated for treatment of COVID-19 because there is no approved treatment for the disease and there is information that suggests it might help some patients recover from COVID-19. Renown Health and the University of Nevada, Reno School of Medicine (UNR Med) are leading a study locally to better understand how the body’s immune system responds to the virus, how it presents in northern Nevada and ultimately, aid in developing a new treatment for COVID-19. “Renown and UNR Med are at the forefront of conducting essential research to increase the health and safety of our community,” said Sara Healy, MD, MPH, principal investigator of the study and a pediatric infectious disease physician at Renown Children’s Hospital and UNR Med. “So little is known about effectively treating COVID-19 and we are venturing into new territory. This important study is instrumental in helping us understand the immune systems of people who were affected by COVID-19, and with their help, getting us one step closer to finding a treatment for the disease that has significantly impacted our nation and our community.” “COVID-19 survivors are in a unique and exciting position to be a part of something much bigger than the virus,” said Mark Riddle, MD, DrPH, FISTM, associate investigator of the study and Associate Dean for Clinical Research at UNR Med. “As a participant of this study, not only are you helping us to better understand the disease and the chronic health affects it has long term, but it’s a way to help those suffering from the disease to fight it and hopefully recover. We encourage participation in this important study and invaluable contributions to advancing medicine and our knowledge of COVID-19.” This community-wide study led by physician researchers from Renown Health and UNR Med is a collaborative effort with Vitalant, county and state health districts, Saint Mary’s Medical Center, Northern Nevada Medical Center, Carson Tahoe Health and the VA Sierra Nevada Health Care System, along with the many care providers in our area.   People aged 18-60 in general good health who have fully recovered from COVID-19 for at least two weeks are encouraged to consider donating convalescent plasma as part of this study. There are 332 people, just in Washoe County (as of 5/1/20) who have recovered from COVID-19 and have immune systems that may now be producing antibodies to protect them from becoming infected again with coronavirus. Donated plasma is needed right now, for this clinical trial to determine definitively if this treatment works. Participating in this research study will also make it easier to donate plasma to the Mayo Clinic convalescent plasma program that Renown is a part of in hopes to find a treatment for COVID-19. There is no cost to participate in this study and participation is voluntary. An individual’s decision to participate will not affect their current or future relations with their health care provider(s), health district, or the community. Those who decide to participate are free to withdraw at any time. Confirmed COVID-19 patients who have recovered from the virus and are interested in participating in the study are invited to contact the project coordinators at the Renown Research Office at (775) 982-3646, or via e-mail at covidplasmascreening@renown.org, 7:30 a.m. – 5 p.m., Monday through Friday.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org. About the University of Nevada, Reno School of Medicine The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Established in 1969, UNR Med is improving the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

    Read More About Seeking Donors Who Have Recovered from COVID-19 to Donate Plasma

    • Thursday, May 07, 2020

    New Automated Robot System in Renown Health

    Renown Health announced today that it is now using ARxIUM’s Robotic IV Automation (RIVA) system in its pharmacy to streamline the production process of IV admixtures. RIVA is a fully automated compounding system designed to precisely and accurately prepare IV syringes and bags in hospital pharmacies. This state-of-the-art system is considered the gold standard when it comes to safety, effectiveness and precision in pharmacy technology. To operate the robot, pharmacists and pharmacy technicians load drugs into the machine, in addition to drug vials, syringes and IV bags. Everything that goes into RIVA receives a barcode as it’s loaded to help the robot identify each item. The operator then instructs the robot to create the drug and RIVA goes to work, allowing employees to go about other duties as the robot maximizes efficiency. RIVA validates each component during the admixture process including size, barcode and weight of each ingredient to ensure accuracy. For an added level of safety, RIVA uses high-intensity pulsed ultraviolet light for disinfection of all vial and bag parts prior to compounding the drugs. “The contamination of IV products usually comes from humans – from our skin, breath, hair or other particles in the air,” said Renown Regional Medical Center’s pharmacy manager, Derek Gillespie. “Plus, the repetitive process of a human mixing 100 items of the same thing and the possibility for distraction can lead to errors. By automating the complex admixture process using the RIVA system, we’re able to significantly reduce the risk of contamination and human error.”  RIVA has the continuous capability to learn how to produce new admixtures through detailed programming done by pharmacists and pharmacy technicians. The system stores the information so it can recreate the drug whenever it’s instructed to do so.  With the help of pharmacy staff, RIVA produces a batch of approximately 50 items at a time, and can make up to 500 admixtures a day. By using RIVA, the pharmacy’s goal is to have items available on hand to help meet patients’ needs quickly. Additionally, in the case of a drug shortage, RIVA would enable the pharmacy to make its own IV solutions or admix items unavailable for purchase.  Only 27 pharmacies in the country currently use the RIVA system. Up until recently, Renown’s pharmacy team did all of its admixtures manually. “It’s exciting to have this new technology in our pharmacy and to know that at Renown Health, we are leveraging the latest technology out there to make our patients as safe as possible,” said Tony Slonim, MD, DrPH, president and CEO of Renown. “Our staff takes pride in using technology like the RIVA system as it allows them to hone their craft on the best technology in the field. We look forward to maximizing our IV production capabilities and fulfilling our patient’s needs more efficiently than ever thanks to RIVA and the incredible team that operates the robot.” For b-roll of RIVA in action and an interview from Derek Gillespie, click here.     About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org About ARxIUM Based in Winnipeg, Manitoba and Buffalo Grove, Illinois, ARxIUM is an industry-leading developer of pharmacy automation, workflow and consulting solutions that improve safety, productivity and workflow. The company provides solutions to shared service centers and health system, hospital, long-term care, retail and government pharmacies. ARxIUM is the developer of the only fully automated IV compounding system in the market today, and offers automated packaging, dispensing, vial filling and high volume systems. In addition, the company provides inventory management, scheduling and workflow software, technical consulting, and system implementation assistance, among other services. ARxIUM is also the creator of the Pharmacy 4.0 approach, which seamlessly converges clinical pharmacy, central production and automation advancements into fully automated, interactive data processes. The approach allows pharmacies to better monitor and react in real-time to address patient care and medication delivery demands. For more information, visit www.arxium.com.

    Read More About New Automated Robot System in Renown Health

Number of results found: 13
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page # 2 Navigate to next page Page 1 of 2
Skipped to 13 results found. Page 1 of 2